Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance

The androgen receptor is a major driver of prostate cancer and inhibition of its transcriptional activity using competitive antagonists, such as enzalutamide remains a frontline therapy for prostate cancer management. However, the majority of patients eventually develop drug resistance. We propose t...

Descripción completa

Detalles Bibliográficos
Autores principales: Salami, Jemilat, Alabi, Shanique, Willard, Ryan R., Vitale, Nick J., Wang, Jing, Dong, Hanqing, Jin, Meizhong, McDonnell, Donald P., Crew, Andrew P., Neklesa, Taavi K., Crews, Craig M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123676/
https://www.ncbi.nlm.nih.gov/pubmed/30271980
http://dx.doi.org/10.1038/s42003-018-0105-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123676/
https://www.ncbi.nlm.nih.gov/pubmed/30271980
http://dx.doi.org/10.1038/s42003-018-0105-8

Ejemplares similares